Journal Article

Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement

Hyde, Matthew A., Ilinykh, Philipp A., Williamson, Lauren E., Carnahan, Robert H., Velazquez, Jalene V., Subramani, Chandru, Gilchuk, Pavlo, Kuzmina, Natalia A., Jurado-Cobena, Eduardo, Crowe, James E., Alter, Galit, Bukreyev, Alexander, Zhou, Fuchun, Huang, Kai, Gunn, Bronwyn M., Kedarinath, Kritika

2024

Overview

Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute the protection conferred by antibodies of various epitope specificities. At the same time, the role of the complement system remains unclear. Here, we compare complement activation by two groups of representative monoclonal antibodies (mAbs) interacting with the glycan cap (GC) or the membrane-proximal external region (MPER) of GP. Binding of GC-specific mAbs to GP induces complement-dependent cytotoxicity (CDC) in the GP-expressing cell line via C3 deposition on GP in contrast to MPER-specific mAbs. In the mouse model of EBOV infection, depletion of the complement system leads to an impairment of protection exerted by one of the GC-specific, but not MPER-specific mAbs. Our data suggest that activation of the complement system represents an important mechanism of antiviral protection by GC antibodies. An analysis of the complement activation by human monoclonal antibodies to Ebola virus glycoprotein suggests the distinct mechanisms for antibodies targeting the glycan cap versus antibodies against the membrane-proximal external region.

• Publisher: Nature Publishing Group UK